Showing results (171-180 of 182) with videos related to
Sort By:
Pageof 19
Annals of Neurology|December 1, 1991
Inter- and intra-examiner reliability of nerve conduction measurements in normal subjectsV Chaudhry, D R Cornblath, E D Mellits, et al.Neurology|May 12, 2010
Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIVC L Cherry, J S Affandi, B J Brew, et al.Cell Death and Differentiation|April 29, 2006
NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degenerationL Conforti, G Fang, B Beirowski, et al.Journal of Medicinal Chemistry|January 19, 1996
Investigation of (Oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral aminesJ Alexander, D S Bindra, J D Glass, et al.American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|March 26, 2011
Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosisN Ticozzi, C Vance, A L Leclerc, et al.Journal of Medicinal Chemistry|November 8, 1996
Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugsJ H Hutchinson, J J Cook, K M Brashear, et al.Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitorsG D Hartman, M E Duggan, W F Hoffman, et al.The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongationJ J Cook, G R Sitko, M A Holahan, et al.Circulation|August 5, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injuryJ J Cook, J D Glass, G R Sitko, et al.Neurology|March 7, 2008
New VAPB deletion variant and exclusion of VAPB mutations in familial ALSJ E Landers, A L Leclerc, L Shi, et al.Pageof 19